RU2008152440A - ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ - Google Patents
ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ Download PDFInfo
- Publication number
- RU2008152440A RU2008152440A RU2008152440/04A RU2008152440A RU2008152440A RU 2008152440 A RU2008152440 A RU 2008152440A RU 2008152440/04 A RU2008152440/04 A RU 2008152440/04A RU 2008152440 A RU2008152440 A RU 2008152440A RU 2008152440 A RU2008152440 A RU 2008152440A
- Authority
- RU
- Russia
- Prior art keywords
- pyrido
- pyrazine
- methoxy
- disorders
- methyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 11
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 40
- 125000000217 alkyl group Chemical group 0.000 claims abstract 22
- 125000005843 halogen group Chemical group 0.000 claims abstract 18
- 125000003118 aryl group Chemical group 0.000 claims abstract 8
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims abstract 6
- 125000005842 heteroatom Chemical group 0.000 claims abstract 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract 6
- 125000003342 alkenyl group Chemical group 0.000 claims abstract 5
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract 5
- 125000004429 atom Chemical group 0.000 claims abstract 4
- 125000006413 ring segment Chemical group 0.000 claims abstract 3
- 229920006395 saturated elastomer Polymers 0.000 claims abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract 2
- 125000001624 naphthyl group Chemical group 0.000 claims abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 37
- 208000035475 disorder Diseases 0.000 claims 36
- -1 di-C 1-3 alkylamino Chemical group 0.000 claims 26
- 208000028017 Psychotic disease Diseases 0.000 claims 15
- 208000019022 Mood disease Diseases 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 8
- 239000001257 hydrogen Substances 0.000 claims 7
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical compound N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 claims 7
- 238000004519 manufacturing process Methods 0.000 claims 6
- 206010026749 Mania Diseases 0.000 claims 5
- 208000022821 personality disease Diseases 0.000 claims 5
- 208000024891 symptom Diseases 0.000 claims 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims 4
- 230000001684 chronic effect Effects 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000020016 psychiatric disease Diseases 0.000 claims 4
- 208000019901 Anxiety disease Diseases 0.000 claims 3
- 206010010904 Convulsion Diseases 0.000 claims 3
- 208000020401 Depressive disease Diseases 0.000 claims 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010029333 Neurosis Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims 3
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 3
- 230000003542 behavioural effect Effects 0.000 claims 3
- 208000010877 cognitive disease Diseases 0.000 claims 3
- 208000013403 hyperactivity Diseases 0.000 claims 3
- 230000001771 impaired effect Effects 0.000 claims 3
- 230000005764 inhibitory process Effects 0.000 claims 3
- 201000000980 schizophrenia Diseases 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 208000024254 Delusional disease Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000012661 Dyskinesia Diseases 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 150000001204 N-oxides Chemical class 0.000 claims 2
- 208000020114 Schizophrenia and other psychotic disease Diseases 0.000 claims 2
- 208000024791 Schizotypal Personality disease Diseases 0.000 claims 2
- 208000027520 Somatoform disease Diseases 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 125000000304 alkynyl group Chemical group 0.000 claims 2
- 150000008064 anhydrides Chemical class 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 210000003169 central nervous system Anatomy 0.000 claims 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 claims 2
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 2
- 208000015238 neurotic disease Diseases 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 229910052763 palladium Inorganic materials 0.000 claims 2
- 208000002851 paranoid schizophrenia Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 230000000506 psychotropic effect Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- UDNUOLCZLGBXAO-UHFFFAOYSA-N 10-(difluoromethoxy)-4-hydroxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 12-methoxy-10,11-dimethyl-4-(4-methyl-2-propylimidazol-1-yl)-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound FC(OC1=C(CN(C2=C1N=CC=1N2CN(C1)O)CCC)C)F.CC1=C(C=2N=CC=3N(C2N(C1OC)CCC)CN(C3)N3C(=NC(=C3)C)CCC)C UDNUOLCZLGBXAO-UHFFFAOYSA-N 0.000 claims 1
- XYIXJTACGCDAFJ-UHFFFAOYSA-N 10-[(2,4-dichlorophenyl)methoxy]-13-ethyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2OCC1=CC=C(Cl)C=C1Cl XYIXJTACGCDAFJ-UHFFFAOYSA-N 0.000 claims 1
- CKPJJTZLDTXSLI-UHFFFAOYSA-N 10-[(2-chloro-6-fluorophenyl)methoxy]-13-ethyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2OCC1=C(F)C=CC=C1Cl CKPJJTZLDTXSLI-UHFFFAOYSA-N 0.000 claims 1
- LLSHTTMEZXTSTQ-UHFFFAOYSA-N 10-[(2-chloro-6-fluorophenyl)methoxy]-4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2OCC1=C(F)C=CC=C1Cl LLSHTTMEZXTSTQ-UHFFFAOYSA-N 0.000 claims 1
- SKKJBUVASPYLCP-UHFFFAOYSA-N 10-cyclopentyloxy-13-ethyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 13-ethyl-4-methoxy-11-methyl-10-propoxy-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N1=CC2=CN(OC)CN2C2=C1C(OCCC)=C(C)CN2CC.N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2OC1CCCC1 SKKJBUVASPYLCP-UHFFFAOYSA-N 0.000 claims 1
- HDEZRZBDCNJDLJ-UHFFFAOYSA-N 12-methoxy-10,11-dimethyl-4-(4-methylpiperazin-1-yl)-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound CCCN1C(OC)C(C)=C(C)C(N=CC2=C3)=C1N2CN3N1CCN(C)CC1 HDEZRZBDCNJDLJ-UHFFFAOYSA-N 0.000 claims 1
- AMMSNBPHGKUYGX-UHFFFAOYSA-N 13-ethyl-4-methoxy-11-methyl-10-[(2,3,6-trifluorophenyl)methoxy]-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2OCC1=C(F)C=CC(F)=C1F AMMSNBPHGKUYGX-UHFFFAOYSA-N 0.000 claims 1
- AHLZMRUGHBSXPM-UHFFFAOYSA-N 13-ethyl-4-methoxy-11-methyl-10-[(2,4,6-trimethylphenyl)methoxy]-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2OCC1=C(C)C=C(C)C=C1C AHLZMRUGHBSXPM-UHFFFAOYSA-N 0.000 claims 1
- VODYAHMSBGDIQH-UHFFFAOYSA-N 13-ethyl-4-methoxy-11-methyl-10-methylsulfanyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-11-methyl-10-methylsulfanyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2SC.N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2SC VODYAHMSBGDIQH-UHFFFAOYSA-N 0.000 claims 1
- PGDQQHOVGFSIGS-UHFFFAOYSA-N 13-ethyl-4-methoxy-11-methyl-10-methylsulfinyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-11-methyl-10-methylsulfonyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2S(C)=O.N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2S(C)(=O)=O PGDQQHOVGFSIGS-UHFFFAOYSA-N 0.000 claims 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 claims 1
- CNDQETATHMBYDH-UHFFFAOYSA-N 4-(2-ethyl-4-methylimidazol-1-yl)-12-methoxy-10,11-dimethyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound CCCN1C(OC)C(C)=C(C)C(N=CC2=C3)=C1N2CN3N1C=C(C)N=C1CC CNDQETATHMBYDH-UHFFFAOYSA-N 0.000 claims 1
- CHHSJAQLIQXHMP-UHFFFAOYSA-N 4-[(13-ethyl-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)oxymethyl]-3,5-dimethyl-1,2-oxazole Chemical compound N12CN(OC)C=C2C=NC2=C1N(CC)CC(C)=C2OCC=1C(C)=NOC=1C CHHSJAQLIQXHMP-UHFFFAOYSA-N 0.000 claims 1
- HLYBJNNYCZEUJZ-UHFFFAOYSA-N 4-methoxy-10,11-dimethyl-13-pentyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene 4-methoxy-10,11-dimethyl-13-(3,3,3-trifluoropropyl)-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraene Chemical compound CC1=C(C=2N=CC=3N(C2N(C1)CCCCC)CN(C3)OC)C.CC3=C(C=1N=CC=2N(C1N(C3)CCC(F)(F)F)CN(C2)OC)C HLYBJNNYCZEUJZ-UHFFFAOYSA-N 0.000 claims 1
- SGGRXRBJGSSIQT-UHFFFAOYSA-N 8-cyclopropylmethoxy-3-methyl-4-methylsulfonylamino-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine Chemical compound CCCN1CC(C)=C(NS(C)(=O)=O)C(N=CC2=C3)=C1N2CN3OCC1CC1 SGGRXRBJGSSIQT-UHFFFAOYSA-N 0.000 claims 1
- IDUMJWOBOYQMGT-UHFFFAOYSA-N 8-difluoromethoxy-3-methyl-4-methylsulfonylamino-1-propyl-imidazo[1,5-a]pyrido[3,2-e]pyrazine Chemical compound N12CN(OC(F)F)C=C2C=NC2=C1N(CCC)CC(C)=C2NS(C)(=O)=O IDUMJWOBOYQMGT-UHFFFAOYSA-N 0.000 claims 1
- 208000008811 Agoraphobia Diseases 0.000 claims 1
- 206010001540 Akathisia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000036640 Asperger disease Diseases 0.000 claims 1
- 201000006062 Asperger syndrome Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- FRGBCXCPLJMXSU-UHFFFAOYSA-N C(#N)C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C.C(#N)C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C Chemical compound C(#N)C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C.C(#N)C1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C FRGBCXCPLJMXSU-UHFFFAOYSA-N 0.000 claims 1
- CUNOIBNJEWZQLY-UHFFFAOYSA-N C(C)N1CC(=C(C=2N=CC=3N(C21)CN(C3)OC)OC(C)C)C.COC3=C(C=NC2=C3N=CC=3N2CN(C3)OC)C Chemical compound C(C)N1CC(=C(C=2N=CC=3N(C21)CN(C3)OC)OC(C)C)C.COC3=C(C=NC2=C3N=CC=3N2CN(C3)OC)C CUNOIBNJEWZQLY-UHFFFAOYSA-N 0.000 claims 1
- SUUZQBPJXAPCMG-UHFFFAOYSA-N C(C)OC(=O)[Mg]C(F)F Chemical compound C(C)OC(=O)[Mg]C(F)F SUUZQBPJXAPCMG-UHFFFAOYSA-N 0.000 claims 1
- SBIVEHRSBHADGN-UHFFFAOYSA-N CC1=C(C=2N=CC=3N(C2N(C1)C1=CC=CC=C1)CN(C3)OC)C.CC3=C(C=1N=CC=2N(C1N=C3C(C)C3=CC=CC=C3)CN(C2)OC)C Chemical compound CC1=C(C=2N=CC=3N(C2N(C1)C1=CC=CC=C1)CN(C3)OC)C.CC3=C(C=1N=CC=2N(C1N=C3C(C)C3=CC=CC=C3)CN(C2)OC)C SBIVEHRSBHADGN-UHFFFAOYSA-N 0.000 claims 1
- KCNUYPPVWJOVBO-UHFFFAOYSA-N CC1=C(C=2N=CC=3N(C2N(C1)CCCCCC)CN(C3)OC)C.C3(CCCCC3)N3CC(=C(C=1N=CC=2N(C13)CN(C2)OC)C)C Chemical compound CC1=C(C=2N=CC=3N(C2N(C1)CCCCCC)CN(C3)OC)C.C3(CCCCC3)N3CC(=C(C=1N=CC=2N(C13)CN(C2)OC)C)C KCNUYPPVWJOVBO-UHFFFAOYSA-N 0.000 claims 1
- XZYWJSFVJBKGTK-UHFFFAOYSA-N COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)C)C.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C Chemical compound COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)C)C.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CC)C XZYWJSFVJBKGTK-UHFFFAOYSA-N 0.000 claims 1
- UOJDUUNYGYQDEO-UHFFFAOYSA-N COC1=CCN(C2=C1N=CC=1N2CN(C1)OC)CCC.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C Chemical compound COC1=CCN(C2=C1N=CC=1N2CN(C1)OC)CCC.COC1=C(CN(C2=C1N=CC=1N2CN(C1)OC)CCC)C UOJDUUNYGYQDEO-UHFFFAOYSA-N 0.000 claims 1
- XJCQRSXQWMNSPO-UHFFFAOYSA-N CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)N)C)CCC)=C1.CON1CN3C(C=NC2=C3N(CC(=C2NC(=O)NC)C)CCC)=C1 Chemical compound CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)N)C)CCC)=C1.CON1CN3C(C=NC2=C3N(CC(=C2NC(=O)NC)C)CCC)=C1 XJCQRSXQWMNSPO-UHFFFAOYSA-N 0.000 claims 1
- KINZNAKMKMXZSU-UHFFFAOYSA-N CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)OC)C)CCC)=C1.N1=CC=NC3=C1C=CC=N3 Chemical compound CON1CN2C(C=NC3=C2N(CC(=C3NC(=O)OC)C)CCC)=C1.N1=CC=NC3=C1C=CC=N3 KINZNAKMKMXZSU-UHFFFAOYSA-N 0.000 claims 1
- GJNBAHWMXFEVEJ-UHFFFAOYSA-N CON1CN2C(C=NC3=C2N=CC(=C3SC)C)=C1.CN1CC(=C(C=3N=CC=2N(C31)CN(C2)OC)SC)C Chemical compound CON1CN2C(C=NC3=C2N=CC(=C3SC)C)=C1.CN1CC(=C(C=3N=CC=2N(C31)CN(C2)OC)SC)C GJNBAHWMXFEVEJ-UHFFFAOYSA-N 0.000 claims 1
- SNYNURLVULNTDR-UHFFFAOYSA-N Cl.N1=CC=NC2=C1C=CC=N2 Chemical compound Cl.N1=CC=NC2=C1C=CC=N2 SNYNURLVULNTDR-UHFFFAOYSA-N 0.000 claims 1
- 206010012218 Delirium Diseases 0.000 claims 1
- 208000032538 Depersonalisation Diseases 0.000 claims 1
- 206010012422 Derealisation Diseases 0.000 claims 1
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims 1
- 208000005819 Dystonia Musculorum Deformans Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000027534 Emotional disease Diseases 0.000 claims 1
- 208000000271 Encopresis Diseases 0.000 claims 1
- 208000008967 Enuresis Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000001836 Firesetting Behavior Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 208000011688 Generalised anxiety disease Diseases 0.000 claims 1
- 239000007818 Grignard reagent Substances 0.000 claims 1
- 208000031886 HIV Infections Diseases 0.000 claims 1
- 206010021030 Hypomania Diseases 0.000 claims 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 claims 1
- 208000036626 Mental retardation Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 claims 1
- VYQHVJLYCVBMPP-UHFFFAOYSA-N N-(4-methoxy-11-methyl-13-phenyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)methanesulfonamide Chemical compound C=1N(OC)CN2C=1C=NC(C(=C(C)C1)NS(C)(=O)=O)=C2N1C1=CC=CC=C1 VYQHVJLYCVBMPP-UHFFFAOYSA-N 0.000 claims 1
- OCQLJFPUULXYOX-UHFFFAOYSA-N N-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)-4-methyl-N-(4-methylphenyl)sulfonylbenzenesulfonamide Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2N(S(=O)(=O)C=1C=CC(C)=CC=1)S(=O)(=O)C1=CC=C(C)C=C1 OCQLJFPUULXYOX-UHFFFAOYSA-N 0.000 claims 1
- SPQOJNXJTIXEIH-UHFFFAOYSA-N N-(4-methoxy-11-methyl-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl)-4-methylbenzenesulfonamide Chemical compound N12CN(OC)C=C2C=NC2=C1N(CCC)CC(C)=C2NS(=O)(=O)C1=CC=C(C)C=C1 SPQOJNXJTIXEIH-UHFFFAOYSA-N 0.000 claims 1
- PYLLDDLPBABELC-UHFFFAOYSA-N N-[11-methyl-4-(4-methyl-2-propylimidazol-1-yl)-13-propyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl]methanesulfonamide Chemical compound CCCN1CC(C)=C(NS(C)(=O)=O)C(N=CC2=C3)=C1N2CN3N1C=C(C)N=C1CCC PYLLDDLPBABELC-UHFFFAOYSA-N 0.000 claims 1
- AQVSOTLZRDLYBF-UHFFFAOYSA-N N-[13-(2-chlorophenyl)-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl]methanesulfonamide Chemical compound C=1N(OC)CN2C=1C=NC(C(=C(C)C1)NS(C)(=O)=O)=C2N1C1=CC=CC=C1Cl AQVSOTLZRDLYBF-UHFFFAOYSA-N 0.000 claims 1
- CXHGLSNWXIHCHY-UHFFFAOYSA-N N-[13-(4-fluorophenyl)-4-methoxy-11-methyl-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl]methanesulfonamide Chemical compound C=1N(OC)CN2C=1C=NC(C(=C(C)C1)NS(C)(=O)=O)=C2N1C1=CC=C(F)C=C1 CXHGLSNWXIHCHY-UHFFFAOYSA-N 0.000 claims 1
- AMPNLFUYRQWOIH-UHFFFAOYSA-N N-[4-methoxy-11-methyl-13-(3,3,3-trifluoropropyl)-2,4,8,13-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5,7,10-tetraen-10-yl]methanesulfonamide Chemical compound FC(F)(F)CCN1CC(C)=C(NS(C)(=O)=O)C2=C1N1CN(OC)C=C1C=N2 AMPNLFUYRQWOIH-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 206010057342 Onychophagia Diseases 0.000 claims 1
- 208000012202 Pervasive developmental disease Diseases 0.000 claims 1
- 101710122057 Phospholemman-like protein Proteins 0.000 claims 1
- 208000027030 Premenstrual dysphoric disease Diseases 0.000 claims 1
- 208000001431 Psychomotor Agitation Diseases 0.000 claims 1
- 239000007868 Raney catalyst Substances 0.000 claims 1
- 229910000564 Raney nickel Inorganic materials 0.000 claims 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims 1
- 206010039987 Senile psychosis Diseases 0.000 claims 1
- 201000001880 Sexual dysfunction Diseases 0.000 claims 1
- 206010041250 Social phobia Diseases 0.000 claims 1
- 206010042008 Stereotypy Diseases 0.000 claims 1
- 208000013200 Stress disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000004810 Vascular dementia Diseases 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 150000001298 alcohols Chemical class 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 208000029560 autism spectrum disease Diseases 0.000 claims 1
- 210000004227 basal ganglia Anatomy 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 229960001948 caffeine Drugs 0.000 claims 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 claims 1
- 229930003827 cannabinoid Natural products 0.000 claims 1
- 239000003557 cannabinoid Substances 0.000 claims 1
- 229940065144 cannabinoids Drugs 0.000 claims 1
- 206010007776 catatonia Diseases 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- XQJWKDXYEXGJLE-UHFFFAOYSA-N chembl1083169 Chemical compound C1=C(OC)N=C2N3C(CCC)=NC(C)=C3C(NS(=O)(=O)C(F)(F)F)=NC2=C1 XQJWKDXYEXGJLE-UHFFFAOYSA-N 0.000 claims 1
- XRJAAHKOWFFZJX-UHFFFAOYSA-N chembl1083266 Chemical compound C1=C(OC)N=C2N3C(CC)=NC(C)=C3C(NS(C)(=O)=O)=NC2=C1 XRJAAHKOWFFZJX-UHFFFAOYSA-N 0.000 claims 1
- PAJXSBMFHFVGLO-UHFFFAOYSA-N chembl1083458 Chemical compound C1=C(OC)N=C2N3C(CCC)=NC(C)=C3C(NC(=O)OCC)=NC2=C1 PAJXSBMFHFVGLO-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 230000035606 childbirth Effects 0.000 claims 1
- 150000001805 chlorine compounds Chemical class 0.000 claims 1
- AOGYCOYQMAVAFD-UHFFFAOYSA-N chlorocarbonic acid Chemical class OC(Cl)=O AOGYCOYQMAVAFD-UHFFFAOYSA-N 0.000 claims 1
- 229960003920 cocaine Drugs 0.000 claims 1
- 230000001149 cognitive effect Effects 0.000 claims 1
- 208000026725 cyclothymic disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013663 drug dependence Diseases 0.000 claims 1
- 230000004064 dysfunction Effects 0.000 claims 1
- 208000024732 dysthymic disease Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002996 emotional effect Effects 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 230000001667 episodic effect Effects 0.000 claims 1
- 201000002904 focal dystonia Diseases 0.000 claims 1
- 230000006870 function Effects 0.000 claims 1
- 208000029364 generalized anxiety disease Diseases 0.000 claims 1
- 150000004795 grignard reagents Chemical class 0.000 claims 1
- 239000000380 hallucinogen Substances 0.000 claims 1
- 230000001505 hypomanic effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000013067 intermediate product Substances 0.000 claims 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L magnesium chloride Substances [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims 1
- 229910001629 magnesium chloride Inorganic materials 0.000 claims 1
- FRIJBUGBVQZNTB-UHFFFAOYSA-M magnesium;ethane;bromide Chemical compound [Mg+2].[Br-].[CH2-]C FRIJBUGBVQZNTB-UHFFFAOYSA-M 0.000 claims 1
- 208000024714 major depressive disease Diseases 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 230000003340 mental effect Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 230000003278 mimic effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 201000002901 multifocal dystonia Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 150000002825 nitriles Chemical class 0.000 claims 1
- 229940005483 opioid analgesics Drugs 0.000 claims 1
- 239000007800 oxidant agent Substances 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 208000019906 panic disease Diseases 0.000 claims 1
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 1
- 208000021011 postpartum psychosis Diseases 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000001003 psychopharmacologic effect Effects 0.000 claims 1
- 201000004645 pyromania Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000002899 segmental dystonia Diseases 0.000 claims 1
- 231100000872 sexual dysfunction Toxicity 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 208000013623 stereotypic movement disease Diseases 0.000 claims 1
- 239000000021 stimulant Substances 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical class 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 208000018724 torsion dystonia Diseases 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 208000002271 trichotillomania Diseases 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 2
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 abstract 2
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 abstract 2
- 101100477978 Hypocrea jecorina (strain QM6a) sor6 gene Proteins 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Virology (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Vascular Medicine (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80924206P | 2006-05-30 | 2006-05-30 | |
| US60/809,242 | 2006-05-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2008152440A true RU2008152440A (ru) | 2010-07-10 |
Family
ID=38441604
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2008152440/04A RU2008152440A (ru) | 2006-05-30 | 2007-05-29 | ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US7550465B2 (https=) |
| EP (1) | EP2021342A1 (https=) |
| JP (1) | JP2009538853A (https=) |
| KR (1) | KR20090013834A (https=) |
| CN (1) | CN101454324A (https=) |
| AR (1) | AR061206A1 (https=) |
| AU (1) | AU2007267392A1 (https=) |
| BR (1) | BRPI0712132A2 (https=) |
| CA (1) | CA2651849A1 (https=) |
| CL (1) | CL2007001554A1 (https=) |
| CR (1) | CR10358A (https=) |
| GT (1) | GT200800265A (https=) |
| IL (1) | IL193740A0 (https=) |
| MX (1) | MX2008014569A (https=) |
| NO (1) | NO20085326L (https=) |
| PE (1) | PE20080711A1 (https=) |
| RU (1) | RU2008152440A (https=) |
| SV (1) | SV2009003048A (https=) |
| TW (1) | TW200817400A (https=) |
| WO (1) | WO2007137820A1 (https=) |
| ZA (1) | ZA200807517B (https=) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2576611C2 (ru) * | 2010-07-20 | 2016-03-10 | Сиренейк Фармасьютикалз, Инк. | Способы применения производных циклического амида для лечения шизофрении |
| RU2613201C2 (ru) * | 2010-07-20 | 2017-03-15 | Сиренейк Фармасьютикалз Инк. | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств |
| US12048768B2 (en) | 2017-06-21 | 2024-07-30 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200815436A (en) * | 2006-05-30 | 2008-04-01 | Elbion Ag | 4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them |
| CA2671980C (en) * | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| US20090143392A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Methods of Treating Obesity and Metabolic Disorders |
| US20090143361A1 (en) * | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10 |
| KR20100110804A (ko) * | 2007-11-30 | 2010-10-13 | 와이어쓰 엘엘씨 | 포스포디에스테라제 10의 저해물질로서의 아릴 및 헤테로아릴 융합된 이미다조[1,5-ａ]피라진 |
| EA018927B1 (ru) * | 2008-05-07 | 2013-11-29 | Х. Лундбекк А/С | Способ лечения когнитивного расстройства, ассоциированного с шизофренией |
| US20100120762A1 (en) * | 2008-11-07 | 2010-05-13 | Wyeth | Triazine derivatives as inhibitors of phosphodiesterases |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| CN103476757A (zh) | 2011-02-18 | 2013-12-25 | 阿勒根公司 | 作为磷酸二酯酶10(pde10a)的抑制剂的取代的6,7-二烷氧基-3-异喹啉醇衍生物 |
| US9938269B2 (en) | 2011-06-30 | 2018-04-10 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| JP2014526453A (ja) * | 2011-09-09 | 2014-10-06 | ハー・ルンドベック・アクチエゼルスカベット | ピリジン化合物およびそれらの使用 |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| AU2012334011A1 (en) | 2011-11-09 | 2014-05-15 | AbbVie Deutschland GmbH & Co. KG | Heterocyclic carboxamides useful as inhibitors of phosphodiesterase type 10A |
| MX361539B (es) | 2012-04-25 | 2018-12-10 | Takeda Pharmaceuticals Co | Compuesto heterociclico nitrogenado. |
| EP2873669A4 (en) * | 2012-07-13 | 2015-11-25 | Takeda Pharmaceutical | HETEROCYCLIC CONNECTION |
| US20140045856A1 (en) * | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| UY34980A (es) | 2012-08-17 | 2014-03-31 | Abbvie Inc | Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a |
| EP2895489B1 (en) | 2012-09-17 | 2017-10-18 | AbbVie Deutschland GmbH & Co. KG | Novel inhibitor compounds of phosphodiesterase type 10a |
| WO2014071044A1 (en) | 2012-11-01 | 2014-05-08 | Allergan, Inc. | Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a) |
| US9790203B2 (en) | 2012-11-26 | 2017-10-17 | Abbvie Inc. | Inhibitor compounds of phosphodiesterase type 10A |
| US9200005B2 (en) | 2013-03-13 | 2015-12-01 | AbbVie Deutschland GmbH & Co. KG | Inhibitor compounds of phosphodiesterase type 10A |
| EP2975031A4 (en) | 2013-03-14 | 2017-04-19 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| CN105209462A (zh) | 2013-03-14 | 2015-12-30 | 艾伯维德国有限责任两合公司 | 磷酸二酯酶10a型的新型抑制剂化合物 |
| JP6427491B2 (ja) | 2013-07-03 | 2018-11-21 | 武田薬品工業株式会社 | 複素環化合物 |
| ES2950424T3 (es) | 2013-07-03 | 2023-10-09 | Takeda Pharmaceuticals Co | Compuesto de amida |
| WO2015006689A1 (en) | 2013-07-12 | 2015-01-15 | University Of South Alabama | Treatment and diagnosis of cancer and precancerous conditions using pde10a inhibitors and methods to measure pde10a expression |
| US9200016B2 (en) | 2013-12-05 | 2015-12-01 | Allergan, Inc. | Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A) |
| US10189841B2 (en) | 2015-11-20 | 2019-01-29 | Forma Therapeutics, Inc. | Purinones as ubiquitin-specific protease 1 inhibitors |
| WO2020065583A1 (en) | 2018-09-28 | 2020-04-02 | Takeda Pharmaceutical Company Limited | Balipodect for treating or preventing autism spectrum disorders |
| CN114524808B (zh) * | 2022-02-21 | 2023-10-24 | 深圳市儿童医院 | 一种吡唑衍生物及其作为pde10抑制剂的用途 |
| CN114524806B (zh) * | 2022-02-22 | 2024-09-03 | 深圳市儿童医院 | 一种三氮唑衍生物及其作为pde10抑制剂的用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5055465A (en) * | 1989-05-31 | 1991-10-08 | Berlex Laboratories, Inc. | Imidazoquinoxalinones, their aza analogs and process for their preparation |
| AU657986B2 (en) * | 1991-06-14 | 1995-03-30 | Pharmacia & Upjohn Company | Imidazo(1,5-a)quinoxalines |
| DE19510965A1 (de) * | 1995-03-24 | 1996-09-26 | Asta Medica Ag | Neue Pyrido/3,2-e/pyrazinone mit antiasthmatischer Wirksamkeit und Verfahren zu deren Herstellung |
| US20030032579A1 (en) * | 2001-04-20 | 2003-02-13 | Pfizer Inc. | Therapeutic use of selective PDE10 inhibitors |
| IL149106A0 (en) | 2001-04-20 | 2002-11-10 | Pfizer Prod Inc | Therapeutic use of selective pde10 inhibitors |
-
2007
- 2007-05-18 TW TW096117906A patent/TW200817400A/zh unknown
- 2007-05-24 US US11/753,207 patent/US7550465B2/en not_active Expired - Fee Related
- 2007-05-29 JP JP2009512482A patent/JP2009538853A/ja active Pending
- 2007-05-29 AR ARP070102310A patent/AR061206A1/es unknown
- 2007-05-29 RU RU2008152440/04A patent/RU2008152440A/ru not_active Application Discontinuation
- 2007-05-29 EP EP07725639A patent/EP2021342A1/en not_active Withdrawn
- 2007-05-29 CN CNA2007800193040A patent/CN101454324A/zh active Pending
- 2007-05-29 KR KR1020087031860A patent/KR20090013834A/ko not_active Withdrawn
- 2007-05-29 MX MX2008014569A patent/MX2008014569A/es active IP Right Grant
- 2007-05-29 WO PCT/EP2007/004748 patent/WO2007137820A1/en not_active Ceased
- 2007-05-29 AU AU2007267392A patent/AU2007267392A1/en not_active Abandoned
- 2007-05-29 BR BRPI0712132-6A patent/BRPI0712132A2/pt not_active IP Right Cessation
- 2007-05-29 CA CA002651849A patent/CA2651849A1/en not_active Abandoned
- 2007-05-30 PE PE2007000674A patent/PE20080711A1/es not_active Application Discontinuation
- 2007-05-30 CL CL2007001554A patent/CL2007001554A1/es unknown
-
2008
- 2008-08-28 IL IL193740A patent/IL193740A0/en unknown
- 2008-08-29 ZA ZA200807517A patent/ZA200807517B/xx unknown
- 2008-10-02 SV SV2008003048A patent/SV2009003048A/es active IP Right Grant
- 2008-10-10 CR CR10358A patent/CR10358A/es not_active Application Discontinuation
- 2008-11-27 GT GT200800265A patent/GT200800265A/es unknown
- 2008-12-19 NO NO20085326A patent/NO20085326L/no not_active Application Discontinuation
-
2009
- 2009-05-19 US US12/454,537 patent/US20090239874A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2576611C2 (ru) * | 2010-07-20 | 2016-03-10 | Сиренейк Фармасьютикалз, Инк. | Способы применения производных циклического амида для лечения шизофрении |
| RU2613201C2 (ru) * | 2010-07-20 | 2017-03-15 | Сиренейк Фармасьютикалз Инк. | Способы применения производных циклического амида для лечения опосредуемых сигма-рецепторами расстройств |
| US12048768B2 (en) | 2017-06-21 | 2024-07-30 | Minerva Neurosciences, Inc. | Gastro-resistant controlled release oral dosage forms |
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200807517B (en) | 2009-06-24 |
| GT200800265A (es) | 2010-07-22 |
| PE20080711A1 (es) | 2008-06-14 |
| CL2007001554A1 (es) | 2008-01-18 |
| KR20090013834A (ko) | 2009-02-05 |
| JP2009538853A (ja) | 2009-11-12 |
| EP2021342A1 (en) | 2009-02-11 |
| TW200817400A (en) | 2008-04-16 |
| BRPI0712132A2 (pt) | 2012-01-17 |
| CN101454324A (zh) | 2009-06-10 |
| US20080027064A1 (en) | 2008-01-31 |
| NO20085326L (no) | 2008-12-19 |
| US20090239874A1 (en) | 2009-09-24 |
| AR061206A1 (es) | 2008-08-13 |
| US7550465B2 (en) | 2009-06-23 |
| MX2008014569A (es) | 2008-12-03 |
| CA2651849A1 (en) | 2007-12-06 |
| WO2007137820A1 (en) | 2007-12-06 |
| CR10358A (es) | 2009-01-07 |
| AU2007267392A1 (en) | 2007-12-06 |
| SV2009003048A (es) | 2009-02-11 |
| IL193740A0 (en) | 2009-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008152440A (ru) | ПИРИДО[3,2-e]ПИРАЗИНЫ, ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ 10 И СПОСОБЫ ИХ ПОЛУЧЕНИЯ | |
| JP2009538853A5 (https=) | ||
| RU2744988C2 (ru) | Соединения и композиции для подавления активности shp2 | |
| ES2411604T3 (es) | Compuestos orgánicos | |
| RU2010126622A (ru) | Конденсированные с арилом и гетероарилом имидазо[1, 5-а]пиразины в качестве ингибиторов фосфодиэстеразы 10 | |
| US20240041871A1 (en) | Methods and compositions for sleep disorders and other disorders | |
| ES2610508T3 (es) | Métodos para tratar el síndrome de Down, el síndrome del cromosoma X frágil y el autismo | |
| ES2675799T3 (es) | Moduladores selectivos del receptor esfingosina 1-fosfato heterocíclica | |
| JP2009538852A5 (https=) | ||
| RU2012154447A (ru) | Гетероциклические сульфоновые аллостерические потенциаторы mglur4, композиции и способы лечения неврологических дисфункций | |
| JP2018525432A (ja) | ヒストンデアセチラーゼのヘテロハロ阻害剤 | |
| RU2012121631A (ru) | АРИЛ- И ГЕТЕРОАРИЛСУЛЬФОНЫ КАК АЛЛОСТЕРИЧЕСКИЕ СРЕДСТВА ПОТЕНЦИРОВАНИЯ mGluR4, КОМПОЗИЦИИ И СПОСОБЫ ЛЕЧЕНИЯ НЕВРОЛОГИЧЕСКИХ ДИСФУНКЦИЙ | |
| RU2009103307A (ru) | ПРОИЗВОДНЫЕ ИМИДАЗО[1, 2-a]ПИРИДИН-2-КАРБОКСАМИДОВ, ИХ ПОЛУЧЕНИЕ И ПРИМЕНЕНИЕ В ТЕРАПИИ | |
| ECSP13012852A (es) | Derivados de 6-ciclobutil-1,5-dihidro-pirazolo [3,4-d]pirimidin-4-ona y su uso como inhibidores de pde9a. | |
| RU2005136370A (ru) | Трициклические индоловые производные и их применение в лечении болезни альцгеймера | |
| BR112019014235A2 (pt) | Inibidores bicíclicos de histona desacetilase | |
| KR101802726B1 (ko) | 오렉신 수용체 안타고니스트로서의 프롤린 술폰아미드 유도체 | |
| RS58053B1 (sr) | [1,2,4] triazolo [1,5-a] pirimidin derivati kao proteazomski inhibitori protozoa za tretman parazitskih bolesti kao što je lišmanijaza | |
| US8829002B2 (en) | Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for production and use thereof | |
| JP6949057B2 (ja) | 動物及びヒトの抗トリパノソーマならびに抗リーシュマニア薬 | |
| CN108348524A (zh) | 用于从中风恢复的方法和组合物 | |
| WO2010126527A1 (en) | Methods of treating cns disorders | |
| EP4426279A1 (en) | Akt3 modulators | |
| RU2399621C2 (ru) | ЗАМЕЩЕННЫЕ 2-АЛКИЛАМИНО-3-СУЛЬФОНИЛ-ПИРАЗОЛО[1,5-a]ПИРИМИДИНЫ, АНТАГОНИСТЫ СЕРОТОНИНОВЫХ 5-HT6 РЕЦЕПТОРОВ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ | |
| WO2025072583A1 (en) | Substituted derivatives of isoindoles for use in the treatment of central nervous system disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20110922 |